Table 1– Baseline characteristics and demographics
SPACEUsual care
Patients8995
Age years69±8.069±10.1
Males/females54/3547/48
FEV1 L1.45±0.571.45±0.55
FEV1 % predicted56.04±16.7659.60±17.42
GOLD stage I/II/III/IV7/51/22/98/60/20/7
GOLD 2011 classification A/B/C/D33/25/15/1641/27/9/18
BMI kg·m−228.05±5.627.09±4.9
Under respiratory consultant67
MRC dyspnoea grade 2/3/4/548/24/13/450/22/14/9
Oxygen LTOT/ambulatory/both/none0/1/03/0/1
Smoking history
 Current/ex-/never-smokers18/67/421/68/6
 Exposure pack-years43±31.736±22.4
Comorbidities
 Hypertension3237
 Type II diabetes138
 Heart failure21
 Arthritis3534
 Other4948
Number of comorbidities 0/1/2/3/≥417/31/24/12/516/39/30/8/2
Medication
 SABA7187
 LABA53
 LABA + ICS4563
 LAMA4246
Time since diagnosis years7±6.76±6.2
Number of exacerbations in previous 6 months 0/1/2/3/4/≥546/31/7/3/1/145/33/10/5/1/1
Age on leaving education years15±1.216±1.7
Ethnicity
 White British8793
 Irish12
 Indian10
Lives with
 Alone1921
 Spouse5458
 Family118
 Other58
  • Data are presented as n or mean±sd. SPACE: Self-Management Programme of Activity, Coping and Education; FEV1: forced expiratory volume in 1 s; GOLD: Global Initiative for Chronic Obstructive Lung Disease; BMI: body mass index; MRC: Medical Research Council; LTOT: long-term oxygen therapy; SABA: short-acting β-agonist; LABA: long-acting β-agonist; ICS: inhaled corticosteroid; LAMA: long-acting muscarinic antagonist.